Therapeutically, in vivo studies using mice bearing the murine bladder cancer cell line MB49 showed that systemic administration of CPI-1205 in combination with anti-CTLA4 resulted in better anti-tumor immunity compared with anti-CTLA4 single therapy [72]. Here, CTLA4 is linked to urinary bladder cancer.